Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention

Expert Review of Molecular Diagnostics

Volumn 9, Issue 1, 2009, Pages 1-6

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; UVOMORULIN;

CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHROMOSOME NOR; EDITORIAL; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; GENE INTERACTION; GENE NUMBER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MEDICAL RESEARCH; MOLECULAR EVOLUTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

ANIMALS; ENVIRONMENT; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 58149236437     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.9.1.1     Document Type: Editorial

References (36)

1. Frazer KA, Ballinger DG, Cox DR et al.; International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
2. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118, 1590-1605 (2008).
3. Birney E, Stamatoyannopoulos JA, Dutta A et al.; ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146), 799-816 (2007).
4. [No authors listed]. My genome. So, what. Nature 456(7218), 1 (2008).
5. Ley TJ, Mardis ER, Ding L et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66-72 (2008).
6. Pennisi E. Breakthrough of the year. Human genetic variation. Science 318(5858), 1842-1843 (2007).
7. Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev. Mol. Diagn. 8(1), 29-39 (2008).
8. Vineis P, Brennan P, Canzian F et al. Expectations and challenges stemming from genome-wide association studies. Mutagenesis 23(6), 439-444 (2008).
9. Chanock SJ, Manolio T, Boehnke M et al. Replicating genotype-phenotype associations. Nature 447(7145), 655-660 (2007).
10. Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J. Clin. Oncol. 10, 26(26), 4360-4361 (2008).
11. Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol. (2008) (Epub ahead of print) DOI: 10.1245/s10434-008-0109-0106.
12. Lee C, Morton CC. Structural genomic variation and personalized medicine. N. Engl. J. Med. 358(7), 740-741 (2008).
13. Lupski JR. Structural variation in the human genome. N. Engl. J. Med. 356(11), 1169-1171 (2007).
14. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and revalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
15. Sasako M, Sano T, Yamamoto S et al. for Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med. 359(5), 453-462 (2008).
16. Forman D, Pisani P. Gastric cancer in Japan - honing treatment, seeking causes. N. Engl. J. Med. 359(5), 448-451 (2008).
17. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000).
18. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965).
19. Sakamoto H, Yoshimura K, Saeki N et al.; Study Group of Millennium Genome Project for Cancer. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40(6), 730-740 (2008).
20. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat. Rev. 26(4), 243-255 (2000).
21. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 392(6674), 402-405 (1998).
22. Pharoah PD, Guilford P, Caldas C; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121(6), 1348-1353 (2001).
23. Brooks-Wilson AR et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J. Med. Genet. 41, 508-517 (2004).
24. Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer - aetiology and pathogenesis. Best Pract. Res. Clin. Gastroenterol. 20(4), 721-734 (2006).
25. Norton JA, Ham CM, Van Dam J et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann. Surg. 245, 873-879 (2007).
26. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann. Surg. 247(4), 714-715 (2008).
27. Taylor PR. Prevention of gastric cancer: a miss. J. Natl Cancer Inst. 99(2), 101-103 (2007).
28. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087-1093 (2007).
29. Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358(9), 910-909 (2008).
30. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle - will we get our wish? N. Engl. J. Med. 358(2), 105-107 (2008).
31. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31(1), 33-36 (2002).
32. Liu C, Russell RM. Nutrition and gastric cancer risk: an update. Nutr. Rev. 66(5), 237-249 (2008).
33. Mossé YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215), 930-935 (2008).
34. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
35. Roukos DH. 21-gene assay: challenges and promises in translating personal genomics and whole genome scans into personalized treatment of breast cancer. J. Clin. Oncol. (In press).
36. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).